Franklin Genomic Advancements ETF (HELX)

Currency in USD
33.14
-0.25(-0.75%)
Closed·
33.14-0.09(-0.28%)
·
Day's Range
33.1333.15
52 wk Range
23.7433.87

Key Statistics

Morning Star Rating
Risk Rating
Bid / Ask
-
Prev. Close
33.39
Price Open
33.13
Volume
2,932
Average Vol. (3m)
6,407
1-Year Change
2.39%
Day’s Range
33.13-33.15
52-Week Range
23.74-33.87
Market Cap
16.13B
Expense Ratio
0.50%
How do you feel today about HELX?
Vote to see community's results!
or

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Performance

Name
YTD
3M
1Y
3Y
5Y
10Y
Growth of 10001,0691,1189551,042887-
Fund Return+6.9%+11.84%-4.52%+1.39%-2.37%-
Rank in Category593775150142-
Percentile Rank4226518789-
NTRA5.95%181.69+0.64%6,583
GH4.90%65.46-2.98%14,509
ALNY4.77%481.67+0.12%1,982
INSM4.47%165.76+1.57%5,476
MEDP4.46%528.07+1.32%1,708
ADPT3.85%16.300-5.62%44,534
KRYS3.84%190.23+1.01%4,079
2079403.71%1,117,000-1.41%927
TEM3.56%87.78-3.56%7,822
UTHR3.36%433.34+0.15%1,551

Franklin Genomic Advancements ETF Company Profile

Franklin Templeton ETF Trust - Franklin Genomic Advancements ETF is an exchange traded fund launched by Franklin Resources, Inc. The fund is managed by Franklin Advisers, Inc. It invests in public equity markets of global region. The fund invests in stocks of companies operating across extending and enhancing the quality of human and other life by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, dna sequencing, synthesis or instrumentation sectors. It invests in growth and value stocks of companies across diversified market capitalization. It invests in stocks of companies that are deemed socially conscious in their business dealings and directly promote environmental responsibility. The fund employs fundamental analysis with bottom-up stock picking approach to create its portfolio. It employs internal and external research to create its portfolio. The fund seeks to benchmark the performance of its portfolio against the Russell 3000 Index. Franklin Templeton ETF Trust - Franklin Genomic Advancements ETF was formed on February 25, 2020 and is domiciled in the United States.

Industry
-
Sector
-
0
Equity Type
ETF

FAQ

How is the performance of HELX?

As of 19 Oct 2025, HELX is trading at a price of 33.14, with a previous close of 33.39. The stock has fluctuated within a day range of 33.13 to 33.15, while its 52-week range spans from 23.74 to 33.87.

What is the current price of HELX?

The HELX stock price today is 33.14.

What is the ticker symbol for Franklin Genomic Advancements?

The ticker symbol for Franklin Genomic Advancements is HELX.

What is the HELX premarket price?

HELX's last pre-market stock price is 33.39.

What is the HELX after hours price?

HELX's last after hours stock price is 33.14.

What is the P/E ratio of HELX?

The P/E ratio for HELX is 23.40.

What is HELX?

HELX is an ETF issued by Franklin Templeton Investments and is listed and traded on the New York Stock Exchange

From a Technical Analysis Perspective, Is HELX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

What is the HELX market cap?

The market cap for HELX is 19.88M.

When is the HELX dividend date?

The next dividend date for HELX is 29 Dec 2021.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.